An NCI-designated Comprehensive Cancer Center
Kuo-Ya-Huei

Ya-Huei Kuo, Ph.D.

Associate Professor, Department of Hematologic Malignancies Translational Science
Research Focus
  • Leukemia Biology
As a key researcher in the Department of Hematologic Malignancies Translational Science within Beckman Research Institute of City of Hope, Ya-Huei Kuo runs a laboratory focused on understanding the molecular anatomy of leukemia stem cells, and developing novel methods for targeting and attacking them. She has published dozens of scholarly papers and received the 2012 American Cancer Society Research Scholar Award.
 
Dr. Kuo joined City of Hope in 2008 after a post-doctoral fellowship in Genetics, Hematology and Cancer Biology at University of Massachusetts Medical School.

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

Chen MJ, Kuo YH, Tian XC and Chen TT. (2002) Novel biological activities of fish pro-IGF-I E-peptides: studies on effects of fish pro-IGF-I E-peptides on morphological change, anchorage-independent cell division, and invasiveness in tumor cells.  Gen. Comp. Endocrinol 126(3): 342-351. PMID: 12093122 
 
Kuo YH and Chen TT. (2002) Novel biological activities of pro-IGF-I E-peptides: regulation of morphological differentiation and anchorage-independent growth in neuroblastoma cells.   Exp. Cell Res. 280(1): 75-89. PMID: 12372341 
 
Kuo YH and Chen, TT. (2003) Specific binding of pro-IGF-I E-peptides to putative cell surface receptors on human neuroblastoma cells.  Gen. Comp. Endocrinol. 132(2): 231-240. PMID: 12812770
 
Landrette SF, Kuo YH, Hensen K, Barjesteh van Waalwijk van Doorn-Khosrovani S, Perrat PN, Van de Ven WJ, Delwel R, Castilla LH. (2005) Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11. Blood 105(7): 2900-7. PMID: 15585652
 
Kuo YH, Landrette SF, Heilman SA, Perrat PN, Garrett L, Liu PP, Le Beau MM, Kogan SC, Castilla LH. (2006) Cbfb-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell 9(1): 57-68. PMID: 16413472 (Cover). 
 
Heilman SA, Kuo YH, Valk PJM, Castilla LH. (2006) Cbfb reduces Cbfb-SMMHC-associated acute myeloid leukemia in mice. Cancer Research 66(23): 11214-8. PMID: 17145866 
 
Kuo YH, Gerstein RM, and Castilla LH. (2008) Cbfb-SMMHC impairs differentiation of common lymphoid progenitors and reveals an essential role for RUNX in early B cell development. Blood 111(3): 1543-51. PMID: 17940206; PMCID: PMC2214760
 
Kuo YH, Zaidi SK, Gornostaeva S, Komori T, Stein GS, Castilla LH. (2009) Runx2 induces acute myeloid leukemia in cooperation with Cbfb-SMMHC in mice. Blood 113(14): 3323-32. PMID: 19179305; PMCID: PMC2665897
 
Pulikkan JA, Madera D, Xue L, Bradley P, Landrette SF, Kuo YH, Abbas S, Zhu LJ, Valk P, Castilla LH. (2012) THPO/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling. Blood 120(4): 868-79. PMID: 22613795; PMCID: PMC3412349
 
Jeannet R, Cai, Q, Liu H, Vu H, Kuo YH. (2013) Alcam regulates long-term hematopoietic stem cell engraftment and self-renewal. Stem Cells 31(3): 560-71. PMID: 23280653; PMCID: PMC3832064
 
Dos Santos C. McDonald T, Ho YW, Liu H, Lin A, Forman SJ, Kuo YH*, and Bhatia R*. (2013) The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cell by chemotherapeutic agents. Blood 122(11): 1900-13. PMID: 23896410. (* Equal contribution, co-correspondence) 
 
Hossain DM, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, Moreira D, Swiderski P, Jozwiak A, Kline J, Forman S, Bhatia R, Kuo YH*, and Kortylewski M*. (2014) Leukemia cell-targeted STAT3 silencing and TLR-9-triggering generate systemic antitumor immunity. Blood 123(1): 15-25. PMID: 24169824; PMCID: PMC3879904 (* Equal contribution, co-correspondence)
 
Kortylewski M and Kuo YH. (2014) Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity. OncoImmunology 3(1): e27441. PMID: 24800162; PMCID: PMC4006856
 
Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, Lin A, Chu S, Qi J, Li L, Hsieh Y-T, Dos Santos C, Yuan H, Popa M, Gjertsen BT, Kuo YH, Chen W, Lain S, McCormack E and Bhatia R. (2014) SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell 15(4): 431-46. PMID: 25280219; PMCID: PMC4305398 
 
Kuo YH* and Bhatia R*. (2014). Pushing the Limits: Defeating Leukemia Stem Cells by   Depleting Telomerase. Cell Stem Cell 15, 673-675. PMID: 25479742; PMCID: PMC4394378. (*Correspondence) 
 
Qi J, Singh S, Hua WK, Cai Q, Chao S-W, Li L, Liu H, Ho Y, McDonald T, Lin A, Marcucci G, Bhatia R, Huang W-J, Chang C-I, Kuo YH. (2015) HDAC8 inhibition specifically targets inv(16) acute myeloid leukemia stem cells by restoring p53 acetylation. Cell Stem Cell 17:5, 597-610, PMID: 26387755; PMCID: PMC4636961 (Cover)
 
Zhang Q, Hossain DM, Duttagupta P, Moreira D, Zhao X, Won H, Buettner R, Nechaev S, Majka M, Zhang B, Cai Q, Swiderski P, Kuo YH, Forman S, Marcucci G, and Kortylewski M. (2016) Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood 127(13):1687-700. PMID: 26796361; PMCID: PMC4817311 
 
Kuo YH*, Qi J, Cook GJ. (2016) Regain control of p53: targeting leukemia stem cells by isoform-specific HDAC inhibition. Exp Hematol. 44(5):315-21. PMID: 26923266; PMCID: PMC4841712 (*Correspondence) 
 
Cai Q, Jeannet R, Hua WK, Cook GJ, Zhang B, Qi J, Liu H, Li L, Chen, CC, Marcucci G and Kuo YH. (2016) CBFβ-SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia-initiation in mice. Blood 128(11): 1503-15. PMID: 27443289; PMCID: PMC5025900
In The News